Day One

Download the Full Event Guide for full details

• Understanding how ADC design is critical to efficacy
• Explaining how heterogeneity is a hallmark of advanced prostate cancer and suitability for bispecific ADC development
• Enhancing breadth and durability of ADC response through dual targeting of two prominent prostate antigens

• Building Invenra’s proprietary B-Body and T-Body multispecific platforms for rapid, in-format discovery as well as for simple manufacturing
• Combining two multispecific platforms to provide a rapid screening system to empirically identify optimal bispecific and trispecific ADC target combinations
• Describing generation of a 12×12 matrix of bispecific B-Body antibodies targeting 6 antigens to identify optimal pairs for trispecific T-Body ADCs for breast cancer
• Highlighting two powerful platforms for next-generation ADCs, offering promise for more effective and versatile breast cancer therapies

• Exploring bispecific ADCs as an emerging and promising next-generation ADC modality
• Outlining the rationale behind target combinations for bispecific ADC design
• Assessing the preclinical safety and efficacy of bispecific ADCs in comparison to monospecific ADCs for clinical trials

• Highlighting ADCs targeting two distinct glyco-MUC1 epitopes and MUC4
• Exploring high target expression in multiple solid tumors
• Demonstrating ADC potent activity in vivo and large therapeutic window
• Evaluating the suite of glyco-Mucin epitopes for novel biparatopic ADC development

Download the Full Event Guide for full details

• Presenting development of a novel antifolate linker-drug platform, a toxin class with a clinically validated mechanism of action
• Discussing preclinical development of antifolate-based ADCs across in vitro and in vivo studies
• Outlining antifolate payload mechanism of action and physicochemical properties

• Overviewing GeneQuantum’s integrated conjugation and manufacturing systems, iLDC and iGDC, and applications on our advancing clinical pipelines
• Introducing the world’s first rapid ADC screening platform iDiscovery, enabling high-throughput conjugate evaluation and rapid candidate optimization
• Advancing best-in-class and first-in-class therapeutics through GeneQuantum’s next-generation conjugation technologies

• Introducing XB371 design as a novel belotecan ADC, created with the SMARTag ADC design platform
• Laying out a demonstration of in vitro bystander and ICD activity
• Demonstrating XB371’s potent, cytotoxic activity in TF-expressing CDX and PDX preclinical models

• Addressing challenges of tumor heterogeneity and poor drug penetration of solid tumors with internalization-independent payload release
• Screening and identifying a unique linker using a specific TME enzyme consistently expressed across cancer models for next-generation ADC development
• Achieving superior efficacy and safety with an internalization-independent linker-payload system in ductal carcinoma and squamous carcinoma cell lines

Download the Full Event Guide for full details

• Understanding AOC novel therapeutic approach for targeted oligonucleotide delivery to skeletal and cardiac tissues

• Showcasing early clinical promise of AOCs in treating rare muscle diseases like DM1, FSHD, and DMD

• Explaining AOC platform extension to precision cardiology, expanding the potential of oligonucleotide based therapies

• Discussing how LCB’s sitespecific ConjuAllTM platform enables discrete DAR ADCs with circulation stable bioconjugation
• Leveraging LCB’s proprietary beta-glucuronidase technology to enable unprecedented preclinical therapeutic indexes through tumor selective release and payload activation
• Assessing early clinical safety and efficacy across payload classes to validate the LCB platform

• Explaining biology of novel glucocorticoid receptor modulator (GRM) payload
• Showcasing translational data supporting the multiple mechanisms of action of ABBV-319
• Evaluating preliminary findings from ongoing Phase 1 study

• Showcasing SMARTag® Enhanced Conjugates, designed to improve efficacy and potency through cytotoxic and non-cytotoxic dual payloads combined in a single ADC using our industry-recognized stable linkers
• Presenting novel in vitro and in vivo efficacy, PK, and tolerability data highlighting Enhanced Conjugate impacts on overcoming common barriers to effective treatment
• Highlighting applications of Enhanced Conjugates to Catalent’s ADC pipeline

Download the Full Event Guide for full details

• Building on the past success of ADC-immunotherapy combination therapies
• Contextualizing Disitamab Vedotin-immunotherapy success in bladder cancer
• Outlining additional clinical DV-IO combination response in bladder cancer

• Accessing unique patient populations and enriching enrollment with those more likely to relapse with a comprehensive biomarker approach that integrates CGP, MRD, multi-omics, and RWD
• Detecting molecular response within weeks of therapy initiation and identifying which patients are benefiting 
• Enhancing clinical development and trial designs by using ctDNA for response monitoring to allow for earlier efficacy readouts and as an early surrogate endpoint to support regulatory conversations

• Introducing I-DXd as a B7-H3 directed ADC which has demonstrated efficacy in the Ph1 IDeate-PanTumor01 trial in SCLC and other solid tumor indications
• Outlining interim results from the Ph2 IDeate-Lung01 trial dose optimization stage demonstrated ORR > 50% at the 12 mg/kg dose expansion
• Understanding primary analysis results from the IDeate-Lung01 trial in 2L+ SCLC

• Exploring the various bioanalytical strategies for the pharmacokinetic analysis of ADCs
• Understanding the different approaches (ligand binding versus LC/MS) and the advantages and disadvantages of each platform technology
• Highlighting real world examples of utilization of LC/MS technology for a total PK solution measuring free payload, total antibody, and total ADC

Download the Full Event Guide for full details

• Overcoming synthetic challenges in a phase appropriate manner to realize process improvements and increase scalability
• Enhancing cross-functional and inter-organizational communication to improve quality and supply chain
• Explaining science-based investigations and root cause identification in the face of unexpected process outcomes

• Leveraging rapid screening platforms to optimize conjugation chemistries while minimizing analytical turnaround times
• Converting screening data into robust and scalable manufacturing processes designed to meet clinical demands
• Enabling a seamless transition from early development to GMP manufacturing, ensuring process continuity and regulatory compliance

• Evaluating and optimizing glycan engineering protocol to ensure consistent ADC quality
• Assessing the impact of glycan structure on ADC effector function activity to inform control strategy
• Discussing strategy for glycan enrichment and engineering for ADCs with multiple mechanisms of action

• Exploring strategies for successful tech-transfer in ADC development
• Understanding process scale-up considerations for bioconjugates
• Exploring process characterization and validation approaches to ensure a commercial-ready process

Download the Full Event Guide for full details

• Laying out cell-free manufacturing technology to produce antibodies for site-specific conjugation
• Manufacturing ADCs with highly specialized design and therapeutic capabilities
• Leveraging cell-free manufacturing to meet supply chain demands during ADC scale up

• Exploring quantitative risk and exposure assessment-development of occupational exposure limits, acceptable surface limits and permitted daily exposures
• Undergoing quantitative exposure assessment for worker exposure purposes including validated industrial hygiene air sampling and surface sampling methods
• Reviewing extractables and leachables for bioprocess train and container closure systems for patient safety

• Leveraging resources to sustain early manufacturability assessments
• Promoting communication and stakeholder engagement between manufacturing and discovery teams to uncover golden opportunities
• Shortening ADC manufacturing timelines without increasing associated risk

• Discussing the powerful tools to ensure commercial ready ADC process
• Exploring innovative solution on bioconjugate cost of goods reduction 
• Laying out integrated strategies to ADC commericialization